APELLIS PHARMACT.DL-0001 (1JK F) stock market data APIs
€18.9205
0(0%)
as of February 4, 2026
Try our APIs with
free plan!
APELLIS PHARMACT.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Prev. Close
18.9205
Open
18.9205
High
18.9205
Low
18.9205
52 wk Range
13.88-28.615
Market Cap
2 465 M
P/E Ratio
62.16
Shares Outstanding
127 M
Revenue
1 016 M
EPS
-2.72
Beta
0.239
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get APELLIS PHARMACT.DL-0001 data using free add-ons & libraries
Get APELLIS PHARMACT.DL-0001 Fundamental Data
APELLIS PHARMACT.DL-0001 Fundamental data includes:
- Net Revenue: 1 016 M
- EBITDA: 82 083 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -1.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
APELLIS PHARMACT.DL-0001 News
New
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best high short interest stocks with biggest upside potential. On January 21, Bank of America analyst Tazeen Ahmad upgraded Apellis to Buy from...
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 5.8% higher at $23.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in th...
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI...
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Why Apellis Pharmaceuticals (APLS) is drawing fresh atten...
Get APELLIS PHARMACT.DL-0001 fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
